Royalty Pharma PLC

Royalty Pharma reports a 12.4 % jump in Q4 2025 net income to US$1.15 billion, driven by higher royalty income and lower expenses, while outlining FX‑hedging plans to safeguard FY‑2026 earnings.

Royalty Pharma reports strong Q4 2025 earnings near $210 M, driven by stable royalty portfolio and disciplined capital use, while FX risk shapes 2026 outlook.

Royalty Pharma’s $500 m partnership with Teva to fund TEV‑408—an anti‑IL‑15 antibody—could unlock high‑potential autoimmune therapies and boost RPL’s value while managing risk.

Royalty Pharma’s $275 million deal with Denali Therapeutics to fund Tividenofusp alfa shows how equity‑linked royalties can accelerate late‑stage biotech launches while sharing upside risk.

Royalty Pharma’s Q2 earnings report reveals a decline in income and valuation concerns, serving as a wake-up call for investors.

Royalty Pharma PLC reported mixed Q2 earnings, with revenue surging but profit declining, but raised its 2025 financial guidance despite the setback.

Royalty Pharma PLC reported strong revenue growth in the second quarter, driven by increased royalty receipts, and has raised its 2025 financial guidance.

Royalty Pharma has announced its third quarter 2025 dividend, solidifying its position as a major player in the pharmaceutical industry with a strong stock price and financial metrics.

Royalty Pharma continues to demonstrate its commitment to growth and transparency through dividend payments, new board appointments, and upcoming financial results.

Royalty Pharma has entered into a definitive agreement to acquire Revolution Medicines’ cancer drug for up to $2 billion, marking a significant milestone in the company’s efforts to expand its portfolio and invest in cutting-edge treatments.